Treatment of bronchial secretion disorders, especially in acute bronchitis: acute bronchitis and acute episode of chronic bronchopulmonary diseases.

Oral use.

1 teaspoon of 5 ml contains 100 mg of carbocistein.

Children aged 2 to 5 years: 200 mg divided daily in 2 divided doses, ie 1 spoon, with coffee (5 ml), twice a day. Code>
Children over 5 years of age: 300 mg daily divided into 3 doses, ie one spoon, coffee (5 mL), 3 times a day.
Duration of processing

It should be short of 8 to 10 days.

Pharmacotherapeutic group: MUCOLYTIC, ATC code: R05CB03.

(R; Respiratory system)

Carbocistein is a mucolytic. It exerts its action on the phase of the mucus, presumably by breaking the disulfide bridges of the glycoproteins, and thus promotes the expectoration.

Not applicable.

A history of hypersensitivity to one of the constituents (especially methyl, propyl parahydroxybenzoate and other salts of parahydroxybenzoates)

· Infant (under 2 years of age) (see Warnings and Precautions for Use).
Special Warning

Productive coughs, which represent a fundamental element of broncho-pulmonary defense, must be respected.

The association of mucomodifiers, bronchodilators with antitussives and / or substances, drying (atropinic) secretions is irrational

Mucolytics can induce bronchial overcrowding in infants. Indeed, its capacity for draining bronchial mucus is limited, due to the physiological peculiarities of its respiratory tree. Therefore, they should not be used in infants (see sections Contraindications and adverse effects)

Treatment should be re-evaluated in the event of persistence or aggravation of symptoms or pathology.

Precaution of use

Caution is advised in subjects with peptic ulcers.

This medicinal product contains sodium 13 mg sodium per 5 ml solution, drinkable. To be taken into account in patients following a strict diet.

This medicinal product contains methyl (E218) and propyl (E216) parahydroxybenzoate and an azo coloring agent (red cochineal A (E124)), they may cause allergic reactions (possibly delayed). >

Not applicable.

Not applicable.

Not applicable.


Studies in animals have not shown any teratogenic effect. In the absence of a teratogenic effect in animals, an ill-forming effect in the human species is not expected. Indeed, to date, the substances responsible for malformations in the human species have been shown to be teratogenic in animals in well-conducted studies on two species

In the clinic, no particular malformative or fetotoxic effect has appeared to date. However, follow-up of pregnancies exposed to carbocistein is insufficient to exclude any risk.

Therefore, the use of carbocistein should only be considered during pregnancy if necessary.

There are no data concerning the passage of carbocistein in maternal milk. However, due to its low toxicity, the potential risks to the child appear negligible, if treated with this drug. As a result, breastfeeding is possible.

· Risk of bronchial over-crowding in infants (see sections Contraindications and Warnings and Precautions for Use)

Allergic skin reactions such as pruritus, erythematous rash, urticaria, and angioedema

· Possibility of phenomena, intestinal digestive (gastralgia, nausea, diarrhea).

It is then advisable to reduce the dose.

Treatment of bronchial secretion disorders, especially in acute bronchitis: acute bronchitis and acute episode of chronic bronchopulmonary diseases.